Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Sarcoma 1Osteosarcoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 6pembrolizumab 3Filgrastim 3fludarabine 2Nivolumab 2Mesna 2Ipilimumab 2Ifosfamide 2Gemcitabine 2Etoposide 2Docetaxel 2Cryosurgery 2Carboplatin 2tocilizumab 1tipifarnib 1tanespimycin 1poly ICLC 1montanide ISA 51 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1flt3 ligand protein 1entinostat 1dostarlimab 1cc-486 1X-Rays 1Thrombopoietin 1Therapeutics 1Thalidomide 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × AP 1903 reagent × Dermatologic × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡